TBL1XR1 and myelodysplastic syndrome: Knowledge that the toxicity of excess MeCP2 in MDS is dependent on the ability of MeCP2 to interact with TBL1/TBLR129,30 raises the possibility of pharmacological disruption of the MeCP2-TBL1/TBLR1 interaction as a therapeutic strategy for MDS.